These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12623108)

  • 1. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
    Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
    Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
    Smith CJ; Gali H; Sieckman GL; Higginbotham C; Volkert WA; Hoffman TJ
    Bioconjug Chem; 2003; 14(1):93-102. PubMed ID: 12526698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Kannan R; Volkert WA; Hoffman TJ
    Cancer Res; 2003 Jul; 63(14):4082-8. PubMed ID: 12874010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells.
    Hoffman TJ; Gali H; Smith CJ; Sieckman GL; Hayes DL; Owen NK; Volkert WA
    J Nucl Med; 2003 May; 44(5):823-31. PubMed ID: 12732685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies.
    Kunstler JU; Veerendra B; Figueroa SD; Sieckman GL; Rold TL; Hoffman TJ; Smith CJ; Pietzsch HJ
    Bioconjug Chem; 2007; 18(5):1651-61. PubMed ID: 17663527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor.
    Ma L; Yu P; Veerendra B; Rold TL; Retzloff L; Prasanphanich A; Sieckman G; Hoffman TJ; Volkert WA; Smith CJ
    Mol Imaging; 2007; 6(3):171-80. PubMed ID: 17532883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
    Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
    J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
    Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc(CO)3-DTMA bombesin conjugates having high affinity for the GRP receptor.
    Lane SR; Veerendra B; Rold TL; Sieckman GL; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2008 Apr; 35(3):263-72. PubMed ID: 18355681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.
    Prasanphanich AF; Nanda PK; Rold TL; Ma L; Lewis MR; Garrison JC; Hoffman TJ; Sieckman GL; Figueroa SD; Smith CJ
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12462-7. PubMed ID: 17626788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
    J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
    Jackson AB; Nanda PK; Rold TL; Sieckman GL; Szczodroski AF; Hoffman TJ; Chen X; Smith CJ
    Nucl Med Biol; 2012 Apr; 39(3):377-87. PubMed ID: 22226021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7-14)NH2], in a prostate tumor xenografted mouse model.
    Lane SR; Nanda P; Rold TL; Sieckman GL; Figueroa SD; Hoffman TJ; Jurisson SS; Smith CJ
    Nucl Med Biol; 2010 Oct; 37(7):751-61. PubMed ID: 20870150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.